65 8.3.1. Type d'étude et critères d'inclusion, Caractéristiques biologiques, p.66 ,
69 8.3.2.4. Effets secondaires, p.69 ,
Pédiatrie II Neuroblastome et Medulloblastome, Standards, Options et Recommandations edn, 1999. ,
Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use], Arch Pediatr, issue.7, pp.11834-842, 2004. ,
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report, Journal of Clinical Oncology, vol.27, issue.2, pp.289-297, 2009. ,
DOI : 10.1200/JCO.2008.16.6785
An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma, European Journal of Cancer, vol.34, issue.7, pp.341063-1069, 1998. ,
DOI : 10.1016/S0959-8049(98)00061-6
Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification, JNCI: Journal of the National Cancer Institute, vol.98, issue.17, pp.981193-1203, 2006. ,
DOI : 10.1158/1078-0432.CCR-04-0496
Favorable prognosis for patients 12 to 18 months of age with stage 4 ,
Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology, British Journal of Cancer, vol.83, issue.8, pp.83973-979, 2000. ,
DOI : 10.1054/bjoc.2000.1412
Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children???s Cancer Group Study, Journal of Clinical Oncology, vol.18, issue.6, pp.1260-1268, 2000. ,
DOI : 10.1200/JCO.2000.18.6.1260
Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution, Bone Marrow Transplantation, vol.23, issue.8, pp.789-795, 1999. ,
DOI : 10.1038/sj.bmt.1701737
Scintigraphic response by 123I- metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma, J Clin Oncol, issue.19, pp.223909-3915, 2004. ,
Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma., Journal of Clinical Oncology, vol.9, issue.6, pp.1050-1058, 1991. ,
DOI : 10.1200/JCO.1991.9.6.1050
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial, The Lancet Oncology, vol.9, issue.3, pp.247-256, 2008. ,
DOI : 10.1016/S1470-2045(08)70069-X
NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology., Journal of Clinical Oncology, vol.15, issue.12, pp.87-153433, 1997. ,
DOI : 10.1200/JCO.1997.15.12.3433
Randomized Trial of Prophylactic Granulocyte Colony-Stimulating Factor During Rapid COJEC Induction in Pediatric Patients With High-Risk Neuroblastoma: The European HR-NBL1/SIOPEN Study, Journal of Clinical Oncology, vol.28, issue.21 ,
DOI : 10.1200/JCO.2009.27.3524
The incidence of hearing impairment after successful treatment of neuroblastoma, Klinische P??diatrie, vol.214, issue.4, pp.149-152, 2002. ,
DOI : 10.1055/s-2002-33179
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group, N Engl J Med, issue.16, pp.3411165-1173, 1999. ,
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97, Eur J Cancer, issue.11, pp.441552-1558, 2008. ,
Continued Remission in Children with Neuroblastoma Despite Elevations of Urinary Catecholamine Metabolites, Journal of Pediatric Hematology/Oncology, vol.14, issue.3, pp.202-206, 1992. ,
DOI : 10.1097/00043426-199208000-00004
A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma, Cancer, vol.25, issue.11, pp.982488-2494, 2003. ,
DOI : 10.1002/cncr.11797
Repeated high-dose chemotherapy followed by purged autologous bone marrow transplantation as consolidation therapy in metastatic neuroblastoma., Journal of Clinical Oncology, vol.5, issue.8, pp.1205-1211, 1987. ,
DOI : 10.1200/JCO.1987.5.8.1205
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma, Cochrane Database Syst Rev, vol.2010, issue.5, pp.6301-115 ,
High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group, Pediatric Blood & Cancer, vol.41, issue.4, pp.348-357, 2005. ,
DOI : 10.1016/S0308-2261(86)80011-X
Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies., Journal of Clinical Oncology, vol.14, issue.9, pp.2417-2426, 1996. ,
DOI : 10.1200/JCO.1996.14.9.2417
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial, The Lancet Oncology, vol.6, issue.9, pp.649-658, 2005. ,
DOI : 10.1016/S1470-2045(05)70291-6
28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures, Bone Marrow Transplantation, vol.217, issue.S2, pp.28-118, 2008. ,
DOI : 10.1055/s-2005-836518
Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial, Annals of Internal Medicine, vol.126, issue.8, pp.126600-607, 1997. ,
DOI : 10.7326/0003-4819-126-8-199704150-00002
Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry., Journal of Clinical Oncology, vol.16, issue.3, pp.953-965, 1998. ,
DOI : 10.1200/JCO.1998.16.3.953
1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party, Eur J Cancer, issue.12, pp.332130-2135, 1997. ,
???Megatherapy??? for advanced neuroblastoma???Rationale and role, European Journal of Cancer, vol.31, issue.2, pp.31-134, 1995. ,
DOI : 10.1016/0959-8049(95)00035-H
Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation, Cancer Chemother Pharmacol, vol.16, issue.2, pp.165-169, 1986. ,
Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology, International Journal of Radiation Oncology*Biology*Physics, vol.64, issue.5, pp.1424-1431, 2006. ,
DOI : 10.1016/j.ijrobp.2005.10.020
Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation, Bone Marrow Transplant, vol.14, issue.1, pp.37-46, 1994. ,
Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group., Journal of Clinical Oncology, vol.12, issue.11, pp.122382-2389, 1994. ,
DOI : 10.1200/JCO.1994.12.11.2382
Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection, Medical and Pediatric Oncology, vol.77, issue.4, pp.228-232, 1998. ,
DOI : 10.1002/(SICI)1096-911X(199804)30:4<228::AID-MPO4>3.0.CO;2-I
Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation, Blood, vol.83, issue.10, pp.3085-3089, 1994. ,
Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma, Bone Marrow Transplantation, vol.27, issue.5 ,
DOI : 10.1038/sj.bmt.1702821
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer, pp.578-583, 2011. ,
High-dose melphalan, vincristine, and total-body irradiation with autologous bone marrow transplantation in children with relapsed neuroblastoma: A phase II study, Medical and Pediatric Oncology, vol.28, issue.5, pp.236-240, 1987. ,
DOI : 10.1016/0360-3016(83)90367-X
Comprehensive treatment of advanced neuroblastoma involving autologous bone marrow transplant, Pediatrics International, vol.8, issue.4, pp.493-499, 1995. ,
DOI : 10.1093/biomet/52.1-2.203
13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the childrens cancer study group, Medical and Pediatric Oncology, vol.76, issue.4, pp.307-311, 1992. ,
DOI : 10.7326/0003-4819-97-6-873
Retinoids and cancer, Cancer Chemotherapy and Pharmacology, vol.3, issue.4, pp.207-215, 1979. ,
DOI : 10.1007/BF00254733
Neuroblastoma: Clinical Perspectives, Monoclonal Antibodies, and Retinoic Acid, Annals of Internal Medicine, vol.97, issue.6, pp.873-884, 1982. ,
DOI : 10.7326/0003-4819-97-6-873
Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation., Journal of Clinical Oncology, vol.13, issue.4, pp.894-901, 1995. ,
DOI : 10.1200/JCO.1995.13.4.894
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma, New England Journal of Medicine, vol.363, issue.14, pp.3631324-1334, 2010. ,
DOI : 10.1056/NEJMoa0911123
URL : http://europepmc.org/articles/pmc3086629?pdf=render
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma., Journal of Clinical Oncology, vol.16, issue.1, pp.229-236, 1998. ,
DOI : 10.1200/JCO.1998.16.1.229
Phase I Dose Escalation of Iodine-131???Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study, Journal of Clinical Oncology, vol.24, issue.3, pp.500-506, 2006. ,
DOI : 10.1200/JCO.2005.03.6400
Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004, Nuklearmedizin, vol.45, issue.4, pp.145-151, 2006. ,
I-Meta-Iodobenzylguanidine with Topotecan as a Radiosensitizer in Children with Metastatic Neuroblastoma, Cancer Biotherapy & Radiopharmaceuticals, vol.20, issue.2, pp.195-199, 2005. ,
DOI : 10.1089/cbr.2005.20.195
Long-term results and risk profiles of patients in five consecutive trials, 1979. ,
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy, BMC Cancer, vol.363, issue.14, p.21, 2011. ,
DOI : 10.1056/NEJMoa0911123
Neuroblastoma in adolescents, Cancer, vol.12, issue.2, pp.349-355, 2003. ,
DOI : 10.4267/10608/816
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas, N Engl J Med, issue.18, pp.3131111-1116, 1985. ,
Poor survival for infants with MYCNamplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience, J Clin Oncol, issue.7, pp.271014-1019, 2009. ,
Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup?, Journal of Clinical Oncology, vol.9, issue.6, pp.1037-1044, 1991. ,
DOI : 10.1200/JCO.1991.9.6.1037
Neuroblastoma, Drugs, vol.16, issue.6, pp.1261-1277, 2000. ,
DOI : 10.1038/bjc.1986.239
URL : https://hal.archives-ouvertes.fr/hal-01402853
Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for Neuroblastoma., Journal of Clinical Oncology, vol.10, issue.12, pp.101870-1878, 1992. ,
DOI : 10.1200/JCO.1992.10.12.1870
Treatment Results of Advanced Neuroblastoma With the First Japanese Study Group Protocol, Journal of Pediatric Hematology/Oncology, vol.21, issue.3, pp.190-197, 1999. ,
DOI : 10.1097/00043426-199905000-00006
LMCE3 Treatment Strategy: Results in 99 Consecutively Diagnosed Stage 4 Neuroblastomas in Children Older Than 1 Year at Diagnosis, Journal of Clinical Oncology, vol.18, issue.3, pp.468-476, 2000. ,
DOI : 10.1200/JCO.2000.18.3.468
A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age, Pediatric Blood & Cancer, vol.49, issue.6 ,
DOI : 10.1002/pbc.21139
Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol, J Clin Oncol, vol.23, issue.3, pp.532-540, 2005. ,
Tandem High-Dose Therapy in Rapid Sequence for Children With High-Risk Neuroblastoma, Journal of Clinical Oncology, vol.18, issue.13, pp.182567-2575, 2000. ,
DOI : 10.1200/JCO.2000.18.13.2567
Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study, Journal of Clinical Oncology, vol.20, issue.9, pp.2284-2292, 2002. ,
DOI : 10.1200/JCO.2002.06.060
Promising Therapeutic Targets in Neuroblastoma, Clinical Cancer Research, vol.18, issue.10 ,
DOI : 10.1158/1078-0432.CCR-11-1939
URL : http://clincancerres.aacrjournals.org/content/clincanres/18/10/2740.full.pdf
Targeting ALK in neuroblastoma???preclinical and clinical advancements, Nature Reviews Clinical Oncology, vol.23, issue.7, pp.391-399 ,
DOI : 10.1200/JCO.2005.01.388
URL : http://europepmc.org/articles/pmc3683972?pdf=render
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study., Journal of Clinical Oncology, vol.16, issue.6, pp.162007-2017, 1998. ,
DOI : 10.1200/JCO.1998.16.6.2007
Revel-Vilk S: A sequential treatment algorithm for infants with stage 4s neuroblastoma and massive hepatomegaly, Pediatr Blood Cancer, vol.2012, issue.591, pp.182-184 ,
DOI : 10.1002/pbc.23186
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children., Journal of Clinical Oncology, vol.15, issue.1, pp.85-93, 1997. ,
DOI : 10.1200/JCO.1997.15.1.85
N-myc oncogene and stage iv-s neuroblastoma preliminary observations on ten cases, Cancer, vol.80, issue.9, pp.1960-1967, 1990. ,
DOI : 10.1016/S0022-3476(73)80016-2
URL : http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19900501)65:9<1960::AID-CNCR2820650914>3.0.CO;2-4/pdf
Neuroblastoma stage IV-S: A heterogeneous disease, Medical and Pediatric Oncology, vol.57, issue.6, pp.467-472, 1991. ,
DOI : 10.1038/bjc.1988.24